Pharmacological treatments approved for obesity, including orlistat, bupropion–naltrexone, and GLP-1 receptor agonists such as semaglutide, have also shown limited efficacy in modifying lipedema depots [19]. The gene discussed is GLP1R; the disease is obesity disorder.